Clinical Nutrition Unit, Department of Internal Medicine and Rehabilitation.
Section of Pediatric Surgery, Pediatric Liver and Gut Research Group, Department of Children's Hospital, Pediatric Research Center.
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(12):1505-1510. doi: 10.1097/MEG.0000000000002082.
Details of intestinal failure in the Finnish adult population are unknown. This study aimed to specify the intestinal failure prevalence and to clinically characterize the patient population in Finland.
All Finnish healthcare units with the potential of providing parenteral support received an electronic survey to report whether they had patient(s) aged ≥18 years on long-term (≥120 days) parenteral support due to intestinal failure. Patient details came from patient records. IBM SPSS v.25 was used to analyze descriptive statistics.
Of the 74 patients, 52 were included after confirming parenteral support indication from the records. The adult intestinal failure prevalence for 2017 was 11.7 per million, 95% confidence interval: 8.9-15.3. Most patients were women (69%), and the median age was 62 (45-72) years. Short bowel syndrome was the most frequent intestinal failure mechanism (73%), and surgical complication the most frequent underlying diagnosis (29%). Of patients, 66% represented the clinical classification category parenteral nutrition 1 or parenteral nutrition 2. Median Charlson Comorbidity Index was one (0-2.8); hypertension (37%) and diabetes (23%) were the most frequent comorbidities. Patients received seven (3.5-7) parenteral support infusions weekly, and eight patients (15%) were on fluids and electrolytes only. The median duration of parenteral support was 27.5 (11.3-57.3) months. Ten patients ceased parenteral support during 2017 after a median of 20.0 (9.0-40.3) parenteral support months. Eight weaned off parenteral support, one ran out of catheter sites, and one died.
Prevalence and patient characteristics of adult intestinal failure in Finland are similar to those in other Western countries.
芬兰成年人的肠衰竭细节尚不清楚。本研究旨在明确肠衰竭的患病率，并对芬兰患者人群进行临床特征分析。
所有有能力提供肠外支持的芬兰医疗单位都收到了一份电子调查，以报告他们是否有年龄≥18 岁的患者因肠衰竭而长期（≥120 天）接受肠外支持。患者详细信息来自患者记录。使用 IBM SPSS v.25 进行描述性统计分析。
在确认记录中的肠外支持指征后，74 名患者中有 52 名被纳入。2017 年成人肠衰竭患病率为 11.7/百万人，95%置信区间：8.9-15.3。大多数患者为女性（69%），中位年龄为 62（45-72）岁。短肠综合征是最常见的肠衰竭机制（73%），手术并发症是最常见的潜在诊断（29%）。在患者中，66%属于肠外营养 1 或肠外营养 2 临床分类类别。中位 Charlson 合并症指数为 1（0-2.8）；最常见的合并症是高血压（37%）和糖尿病（23%）。患者每周接受 7（3.5-7）次肠外支持输注，8 名患者（15%）仅接受液体和电解质。肠外支持的中位持续时间为 27.5（11.3-57.3）个月。2017 年，10 名患者在中位 20.0（9.0-40.3）肠外支持月后停止了肠外支持。其中 8 名患者成功撤机，1 名患者因导管部位用尽而停止，1 名患者死亡。
芬兰成人肠衰竭的患病率和患者特征与其他西方国家相似。
